Cardiol Therapeutics INC. (CRDL) — SEC Filings

Overview

Cardiol Therapeutics INC. (CRDL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 14, 2026: Cardiol Therapeutics Inc. filed a Form 6-K on April 14, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K form itself and Exhibit 99.1, along with a graphic file. The company's mailing and business addresses are both listed as 602-2265 Upper Middle

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 5 bullish, 45 neutral. The dominant filing sentiment for Cardiol Therapeutics INC. is neutral.

Filing Type Overview

Cardiol Therapeutics INC. (CRDL) has filed 48 6-K, 1 SC 13G/A, 1 20-F with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Cardiol Therapeutics Files 6-K Report — 6-K · Apr 14, 2026 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 14, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K for
• Cardiol Therapeutics Files 6-K Report — 6-K · Apr 10, 2026 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 10, 2026, reporting information as a foreign issuer. The filing includes documents such as the 6-K form itse
• Cardiol Therapeutics Files 6-K Report — 6-K · Apr 1, 2026 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 1, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K form
• 6-K Filing — 6-K · Dec 1, 2025
• 6-K Filing — 6-K · Nov 13, 2025
• Cardiol Therapeutics Secures U.S. Patent for Heart Drugs Until 2040 — 6-K · Nov 13, 2025 Risk: low
  Cardiol Therapeutics Inc. announced on November 13, 2025, that it has received a U.S. patent allowance for its heart drugs, providing broad protection until lat
• 6-K Filing — 6-K · Nov 5, 2025
• Cardiol Therapeutics Files 6-K with Exempt Distribution Report — 6-K · Oct 28, 2025 Risk: medium
  Cardiol Therapeutics Inc. filed a Form 6-K on October 28, 2025, reporting on activities for the month of October 2025. The filing includes Exhibit 99.1, a Form
• Cardiol Therapeutics Files Material Change Report — 6-K · Oct 27, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on October 27, 2025, reporting a Material Change Report dated October 27, 2025. The company, based in Oakville, Ontar
• Cardiol Therapeutics Raises $11.4M, Extends Cash Runway — 6-K · Oct 21, 2025 Risk: medium
  Cardiol Therapeutics Inc. announced on October 21, 2025, that it has successfully completed a financing round, raising US$11.4 million. This funding is expected
• Cardiol Therapeutics Secures $11M Financing — 6-K · Oct 17, 2025 Risk: medium
  Cardiol Therapeutics Inc. announced on October 17, 2025, that it has secured US$11 million in financing. This funding is expected to extend the company's cash r
• Cardiol Therapeutics Files Q2 2025 Results — 6-K · Aug 14, 2025 Risk: medium
  Cardiol Therapeutics Inc. filed a Form 6-K on August 14, 2025, reporting its financial results for the three and six months ended June 30, 2025. The filing incl
• Cardiol Therapeutics to Speak at Canaccord Growth Conference — 6-K · Aug 11, 2025 Risk: low
  Cardiol Therapeutics Inc. announced on August 11, 2025, its participation in a fireside chat at Canaccord Genuity's 45th Annual Growth Conference. The company,
• Cardiol Therapeutics Announces Phase II Trial Results — 6-K · Aug 6, 2025 Risk: medium
  Cardiol Therapeutics Inc. announced topline results from its Phase II ARCHER trial of CardiolRx™ in acute myocarditis on August 6, 2025. The company filed a For
• Cardiol Therapeutics Locks Phase II ARCHER Trial Database — 6-K · Jul 22, 2025 Risk: medium
  Cardiol Therapeutics Inc. announced on July 22, 2025, that it has achieved database lock for its Phase II ARCHER trial of CardiolRx™ in patients with acute myoc
• Cardiol Therapeutics Reports 2025 AGM Results — 6-K · May 29, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on May 29, 2025, reporting the results of its 2025 Annual General Meeting of Shareholders. The filing includes a news
• Cardiol Therapeutics to Webcast Annual Shareholder Meeting — 6-K · May 27, 2025 Risk: low
  Cardiol Therapeutics Inc. announced on May 27, 2025, that it will webcast its Virtual Annual General Meeting of Shareholders on May 28, 2025, at 4:30 p.m. EDT.
• Cardiol Therapeutics Files May 2025 6-K with Q1 Financials — 6-K · May 14, 2025 Risk: medium
  Cardiol Therapeutics Inc. filed a Form 6-K on May 14, 2025, reporting on its activities for the month of May 2025. The filing includes condensed interim consoli
• Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board — 6-K · Apr 29, 2025 Risk: low
  Cardiol Therapeutics Inc. announced on April 29, 2025, the nomination of Dr. Timothy Garnett to its Board of Directors. Dr. Garnett brings extensive experience
• Cardiol Therapeutics Files 6-K for April 2025 Shareholder Meeting — 6-K · Apr 28, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 28, 2025, for the month of April 2025. The filing includes several exhibits related to their Annual General
• Cardiol Therapeutics Files 6-K — 6-K · Apr 16, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 16, 2025, to report a news release dated April 16, 2025. The filing does not contain specific financial figu
• Cardiol Therapeutics Files 6-K with April News Release — 6-K · Apr 1, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 1, 2025, reporting for the month of April 2025. The filing includes a news release dated April 1, 2025, as E
• Cardiol Therapeutics Files 6-K with Meeting Notice — 6-K · Mar 14, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on March 14, 2025, reporting a Notice of Meeting and Record Date dated March 14, 2025. The company, headquartered in
• Cardiol Therapeutics Files 6-K Report — 6-K · Mar 3, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on March 3, 2025, reporting information for the month of March 2025. The filing includes a news release dated March 3
• Cardiol Therapeutics Files 6-K for February 2025 — 6-K · Feb 20, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on February 20, 2025, reporting for the month of February 2025. The filing, submitted by newsfilecorp.com, includes E
• Cardiol Therapeutics Files 6-K for February 2025 — 6-K · Feb 4, 2025 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on February 4, 2025, reporting for the month of February 2025. The filing indicates that the company is a foreign pri
• Cardiol Therapeutics Files 6-K Report — 6-K · Nov 18, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on November 18, 2024, reporting for the month of November 2024. The filing includes Exhibit 99.1, which is a news rel
• Cardiol Therapeutics Files 6-K with Q3 Financials — 6-K · Nov 14, 2024 Risk: medium
  Cardiol Therapeutics Inc. filed a 6-K report on November 14, 2024, for the period ending September 30, 2024. The filing includes condensed interim consolidated
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• Cardiol Therapeutics Files 6-K, Reports for October 2024 — 6-K · Oct 22, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on October 22, 2024, reporting for the month of October 2024. The company, based in Oakville, Ontario, Canada, is inv
• Cardiol Therapeutics Closes $10M Financing — 6-K · Oct 11, 2024 Risk: medium
  On October 11, 2024, Cardiol Therapeutics Inc. announced the closing of its previously announced bought-deal financing, which included the exercise of the over-
• Cardiol Therapeutics Closes $13.5M Public Offering — 6-K · Oct 10, 2024 Risk: medium
  Cardiol Therapeutics Inc. announced the closing of a public offering on October 10, 2024, raising US$13.5 million. The company, headquartered in Oakville, Ontar
• Cardiol Therapeutics Inc. Files 6-K, Incorporates Exhibit — 6-K · Oct 9, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on October 9, 2024, to incorporate Exhibit 99.1 by reference into its existing Registration Statement on Form F-10 (F
• Cardiol Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Oct 8, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on October 8, 2024, incorporating Exhibits 99.1 and 99.2 by reference into its Form F-10 registration statement (File
• Cardiol Therapeutics Files 6-K, Includes News Release — 6-K · Sep 24, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on September 24, 2024, reporting for the month of September 2024. The filing indicates that the company is a foreign
• Cardiol Therapeutics Files 6-K Report — 6-K · Sep 10, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on September 10, 2024, to report information for the month of September 2024. The filing includes Exhibit 99.1, which
• Cardiol Therapeutics Files 6-K with Financials — 6-K · Aug 12, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a 6-K report on August 12, 2024, for the period ending June 30, 2024. The filing includes condensed interim consolidated financi
• Cardiol Therapeutics Inc. Files 6-K, Incorporates Exhibit — 6-K · Jul 16, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on July 16, 2024, incorporating Exhibit 99.1 into its existing Registration Statement on Form F-10 (File No. 333-2807
• Cardiol Therapeutics Files 6-K with News Release — 6-K · Jun 27, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on June 27, 2024, reporting a news release as an exhibit. The company, based in Oakville, Ontario, Canada, operates i
• Cardiol Therapeutics Files 6-K Report — 6-K · Jun 25, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on June 25, 2024, reporting a news release dated June 2024. The company, based in Oakville, Ontario, Canada, is invol
• Cardiol Therapeutics Files 6-K with News Release — 6-K · Jun 13, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on June 13, 2024, reporting information for the month of June 2024. The filing includes a news release dated June 13,
• Cardiol Therapeutics Files Annual Meeting Documents — 6-K · May 28, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on May 28, 2024, to report on its Annual General Meeting of Shareholders. The filing includes the Notice of Annual Ge
• Cardiol Therapeutics Files Q1 2024 Financial Update — 6-K · May 14, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on May 14, 2024, reporting its condensed interim consolidated financial statements and management's discussion and an
• Cardiol Therapeutics Files 6-K — 6-K · May 14, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on May 14, 2024, reporting a news release dated May 14, 2024. The company is incorporated in Canada and its principal
• Cardiol Therapeutics Files 6-K with Meeting Notice — 6-K · Apr 26, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 26, 2024, reporting for the month of April 2024. The filing includes Exhibit 99.1, which is a Notice of Meet
• Cardiol Therapeutics Files 6-K Report — 6-K · Apr 2, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K on April 2, 2024, to report information for the month of April 2024. The filing includes Exhibit 99.1, which is a new
• Cardiol Therapeutics Inc. Files 20-F Report for Fiscal Year Ended December 31, 2023 — 20-F · Apr 1, 2024 Risk: low
  Cardiol Therapeutics Inc. (CRDL) filed a Foreign Annual Report (20-F) with the SEC on April 1, 2024. Cardiol Therapeutics Inc. filed its annual report on Form 2
• Cardiol Therapeutics Files 6-K, Confirms 20-F Reporting — 6-K · Feb 26, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K with the SEC on February 26, 2024, indicating it is a foreign private issuer. The filing confirms the company submits
• Cardiol Therapeutics Files 6-K, Confirms 20-F Annual Reporting — 6-K · Feb 21, 2024 Risk: low
  Cardiol Therapeutics Inc. filed a Form 6-K with the SEC on February 21, 2024, indicating its status as a foreign private issuer. The filing confirms the company
• Cardiol Therapeutics Files Routine 6-K for News Release — 6-K · Feb 15, 2024 Risk: low
  Cardiol Therapeutics Inc., a foreign private issuer, filed a Form 6-K with the United States Securities and Exchange Commission on February 15, 2024. The purpos

Risk Profile

Risk Assessment: Of CRDL's 46 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 36 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Chris Waddick
• Dr. Timothy Garnett

Industry Context

Cardiol Therapeutics Inc. operates in the biological products sector, specifically focusing on products that are not diagnostic substances.

Top Tags

news-release (13) · regulatory-filing (9) · biotech (9) · filing (9) · 6-K (7) · sec-filing (6) · foreign-issuer (5) · financing (4) · shareholder-meeting (4) · reporting (4)

Key Numbers

• Patent Expiration Year: 2040 — Indicates long-term protection for intellectual property.
• Commission File Number: 001-40712 — Identifies the specific SEC filing series for Cardiol Therapeutics Inc.
• Financing Raised: US$11.4M — Provides capital for operations and development.
• Cash Runway Extended To: Q3 2027 — Indicates financial stability for future operations.
• Financing Secured: US$11 million — This capital infusion is critical for funding ongoing research and development activities.
• Extended Cash Runway: Q3 2027 — Indicates the company has sufficient funds to operate for an extended period, reducing immediate financial pressure.
• Financial Period: Q1 2025 — The filing includes financial statements and MD&A for this period.
• Reporting Period: Q3 2024 — Financial statements cover the three and nine months ended September 30, 2024.
• Gross Proceeds: $10.0M CAD — Raised from the exercise of the over-allotment option in a bought-deal financing.
• Units Sold: 10,000,000 units — Total number of units sold at $1.00 CAD each.
• Capital Raised: US$13.5M — Funds secured from the public offering to support company operations and growth.
• SEC File Number: 001-40712 — Identifies the company's filing with the SEC.
• Registration Statement File Number: 333-280713 — References the specific registration statement being supplemented.
• Fiscal Year End: 2023-12-31 — The end date of the reporting period.
• Filing Date: 2024-04-01 — The date the 20-F report was submitted.

Frequently Asked Questions